Tim Sandle has participated in an endotoxin / LAL discussion, published in American Pharmaceutical Review. The discussion addresses key issues like low endotoxin recovery, together with future developments in LAL testing.
Here is an extract: “Dr. Tim Sandle: I think the difference between purified LPS and natural endotoxin complexes is established, and they will behave differently under conditions of the test.
The issue of low endotoxin one is important, although the subject is causing some confusion for LAL users. It would be good to get a consensus between the providers of LAL regents together with a clear signal from the regulators.”
The roundtable discussion appears in:
LAL Roundtable, American Pharmaceutical Review, 19(6): 47-51
Posted by Dr. Tim Sandle